Recent Finacing
Recent Raise
Cellusion develops CLS001, an iPS-derived corneal endothelial cell therapy delivered via simple injection for bullous keratopathy, advancing company-sponsored and investigator-led clinical trials and manufacturing partnerships for global distribution.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
